

Press release

February 27th, 2007

Further information

Prof. Dr. Harald Mischak
CSO
Phone: +49 (0)511 55 47 44 13
Fax: +49 (0)511 55 47 44 31
mischak@mosaiques-diagnostics.com

Dr. Harald-Gerhard Geppert
Director Therapeutic & Clinical
Applications
Phone: +49 (0)511 55 47 44 23
Fax: +49 (0)511 55 47 44 31
geppert@mosaiques-diagnostics.com

**mosaiques diagnostics &
therapeutics AG**
Mellendorfer Straße 7-9
D-30625 Hannover
GERMANY
www.mosaiques-diagnostics.com

Worldwide standards for clinical proteome analyses

The dream of individual medicine gets the scientific basis

Hannover - After the many pitfalls of the *GENOMICS*-era, the basis for worldwide standards for clinical proteome research aiming towards early detection of live-threatening diseases as well as evaluation of therapeutic success has been set. With the publication of suggested guidelines in the leading journal "*PROTEOMICS – Clinical Applications*", a team of 26 renowned scientists from international leading research institutes, led by Prof. Harald Mischak (mosaiques diagnostics & therapeutics AG), established the basis for worldwide standards for the clinical definition of diseases by the use of proteome analysis. This task has been significantly eased by the successful application of diagnostic polypeptide patterns in several clinical studies recently. This technological advance already enables the early detection of several diseases, for example bladder cancer, prostate cancer and chronic renal diseases, including diabetic nephropathy. The studies were published recently in *Nature Medicine*, *Blood*, *Lancet Oncology* and the *Journal of the American Society of Nephrology*. Due to the enormous expected impact of these now defined guidelines, the publishers of *PROTEOMICS – Clinical Applications* not only made this article freely available to everybody (<http://www3.interscience.wiley.com/cgi-bin/fulltext/114082342/PDFSTART>), but also informed over 10,000 researchers worldwide about this manuscript via email.

The use of proteome analysis for the early detection differential diagnosis of several diseases is marketed via DiaPat GmbH, a subsidiary of mosaiques diagnostics & therapeutics AG. Clinical proteome analysis is also of high value in the development of pharmaceuticals and will result in faster and safer development. Effects and side-effects of drugs can be evaluated on a multidimensional molecular level with unsurpassed precision using diagnostic polypeptide patterns. **Diagnostic patterns** (DiaPat) are patterns of thousand proteins and peptides, which reflects the difference between healthy and disease, based on indicative changes of specific proteins and peptides. The extremely complex and expensive drug development process can be significantly improved by the DiaPat method, by reducing the rates and the time for drug development.

About mosaiques diagnostics & therapeutics AG

The mosaiques diagnostics & therapeutics AG was founded in 2002 in Hannover (Germany). The company's core competence is the early and reliable detection of diseases based on fast and accurate analysis of proteins and polypeptides in body fluids and the generation of **diagnostic patterns** (DiaPat). Marketable diagnostics for bladder and prostate cancer, chronic renal diseases, diabetic nephropathy, ureteropelvic junction obstruction in newborn and infarct risk are already distributed through the subsidiary DiaPat GmbH. The mosaiques diagnostics & therapeutics AG also performs clinical trials with the pharmaceutical industry that enable improvement of therapy and therapeutics, based on the individual molecular polypeptide signature.